In line with this study, in 2017, an open-label phase 2 study indicated that vemurafenib enhanced the PFS in previously untreated patients with V600 BRAF-driven NSCLC. Regarding toxicity, vemurafenib administration has been described as safe in these patients [104]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.